Difference between revisions of "Levoleucovorin (Fusilev)"
m (Text replacement - "[[Media:" to "[[File:") |
|||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Folic acid analog that is the pharmacologically active isomer of 5-formyl tetrahydrofolic acid (racemic d,l [[Folinic acid (Leucovorin)]]). Counteracts the effects of folic acid antagonists such as [[Methotrexate (MTX) | methotrexate]], which acts by inhibiting dihydrofolate reductase. Enhances the activity of [[Fluorouracil (5-FU)]] by inhibiting thymidylate synthase.<ref name="insert">[https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020140s002lbl.pdf Levoleucovorin (Fusilev) package insert]</ref><ref>[[ | + | Class/mechanism: Folic acid analog that is the pharmacologically active isomer of 5-formyl tetrahydrofolic acid (racemic d,l [[Folinic acid (Leucovorin)]]). Counteracts the effects of folic acid antagonists such as [[Methotrexate (MTX) | methotrexate]], which acts by inhibiting dihydrofolate reductase. Enhances the activity of [[Fluorouracil (5-FU)]] by inhibiting thymidylate synthase.<ref name="insert">[https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020140s002lbl.pdf Levoleucovorin (Fusilev) package insert]</ref><ref>[[File:Levoleucovorin.pdf | Levoleucovorin (Fusilev) package insert (locally hosted backup)]]</ref><ref>[http://fusilev.com/ Fusilev manufacturer's website]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
Revision as of 23:19, 19 September 2021
General information
Class/mechanism: Folic acid analog that is the pharmacologically active isomer of 5-formyl tetrahydrofolic acid (racemic d,l Folinic acid (Leucovorin)). Counteracts the effects of folic acid antagonists such as methotrexate, which acts by inhibiting dihydrofolate reductase. Enhances the activity of Fluorouracil (5-FU) by inhibiting thymidylate synthase.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Note: these are diseases where folinic acid is used as an adjuvant to Fluorouracil (5-FU), as opposed to an antidote as it is used in conjunction with Methotrexate (MTX)
- Cervical cancer
- Cholangiocarcinoma
- Colon cancer
- Esophageal cancer
- Gastric cancer
- Hepatocellular carcinoma
- Pancreatic cancer
- Rectal cancer
Patient drug information
- Levoleucovorin (Fusilev) package insert[1]
- Levoleucovorin (Fusilev) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 3/7/2008: FDA approved "to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists." "Levoleucovorin rescue is indicated after high-dose methotrexate therapy in osteosarcoma."
Also known as
- Generic name: levoleucovorin calcium
- Brand name: Fusilev
References
- Drugs
- Intravenous medications
- Chemotherapy protective agents
- Cervical cancer medications
- Cholangiocarcinoma medications
- Colon cancer medications
- Esophageal cancer medications
- Gastric cancer medications
- Hepatocellular carcinoma medications
- Pancreatic cancer medications
- Rectal cancer medications
- FDA approved in 2008